News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SillaJen To Present At The Biotechnology Industry Organization (BIO) Business Forum



6/20/2014 7:11:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BUSAN, South Korea and SAN FRANCISCO, June 20, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that the company will make a presentation next week at the BIO Business Forum, which is a part of the 2014 BIO International Convention being held in San Diego, CA. David McDonald, chief business officer of SillaJen, will present on Tuesday, June 24, 2014 at 2:15 pm. PT.

About SillaJen, Inc.
SillaJen, Inc., is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company's lead product candidate, Pexa-Vec (JX-594), is entering late-stage clinical development for the treatment of advanced primary liver cancer (Pexa-Vec described in Nature Reviews Cancer, Kirn et al 2009). High-dose Pexa-Vec treatment was associated with an overall survival benefit in a randomized Phase 2 trial in patients with 1st-line liver cancer (Nature Medicine, 2013). Pexa-Vec also demonstrated unique IV delivery to solid tumors, and objective tumor responses, as reported in Nature (2011). Pexa-Vec is in mid-stage development for kidney cancer and other solid tumors. The company is also developing a robust pipeline of oncolytic immunotherapy products with multiple complementary mechanisms-of-action.

Born from a desire to revolutionize therapeutic approaches for patients with serious unmet medical needs, and honed through years of pioneering experience guiding oncolytic vaccinia through clinical trials in Korea, the U.S. and around the world, SillaJen is uniquely poised for rapid and efficient clinical development of cutting-edge gene and viral therapies. SillaJen acquired Jennerex Inc (San Francisco, California) in 2014. SillaJen is headquartered in Busan, South Korea with labs in Busan and offices in San Francisco, California. Additional information about SillaJen can be found at www.sillajen.com.

Contact:
Jennifer Williams
Investor and Media Relations
Cook Williams Communications, Inc.
jennifer@cwcomm.org

SOURCE SillaJen, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES